Evidence map›Paper›PMID 29706321›Full record

Trial reportMolecular metabolism2018

Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes.

Marlies de Ligt, Yvonne M H Bruls, Jan Hansen, Marie-Fleur Habets, Bas Havekes, Emmani B M Nascimento, Esther Moonen-Kornips, Gert Schaart, Vera B Schrauwen-Hinderling, Wouter van Marken Lichtenbelt and 1 more

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Molecular metabolism, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02129595 (Effects of Resveratrol on Insulin Sensitivity, Brown Adipose Tissue and Metabolic Profile in First-degree Relatives of Type 2 Diabetic Patients), which is not on this map. Cited by 46 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 5 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02129595 nacompletednot on this map

Effects of Resveratrol on Insulin Sensitivity, Brown Adipose Tissue and Metabolic Profile in First-degree Relatives of Type 2 Diabetic Patients

TypeinterventionalSponsorMaastricht University Medical CenterRan2014 to 2017Enrolled15ConditionsPre-diabetesArmsplacebo, resveratrol
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 5 syntheses or guidelines pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Effects of resveratrol supplementation on cardiac remodeling in hypertensive patients: a randomized controlled clinical trial.Hypertension research : official journal of the Japanese Society of Hypertension · 2023
    Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Resveratrol as a Regulator of Inflammation, Oxidative Stress, and Glucose Stability in Diabetes.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Marlies de LigtDepartment of Nutrition and Movement Sciences, Maastricht Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, The Netherlands.
Yvonne M H BrulsDepartment of Nutrition and Movement Sciences, Maastricht Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, The Netherlands; Department of Radiology, Maastricht University Medical Centre, NUTRIM School for Nutrition and Translational Research in Metabolism, The Netherlands.
Jan HansenDepartment of Nutrition and Movement Sciences, Maastricht Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, The Netherlands.
Marie-Fleur HabetsDepartment of Nutrition and Movement Sciences, Maastricht Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, The Netherlands.
Bas HavekesDepartment of Internal Medicine, Division of Endocrinology, Maastricht University Medical Centre, The Netherlands.
Emmani B M NascimentoDepartment of Nutrition and Movement Sciences, Maastricht Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, The Netherlands.
Esther Moonen-KornipsDepartment of Nutrition and Movement Sciences, Maastricht Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, The Netherlands.
Gert SchaartDepartment of Nutrition and Movement Sciences, Maastricht Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, The Netherlands.
Vera B Schrauwen-HinderlingDepartment of Nutrition and Movement Sciences, Maastricht Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, The Netherlands; Department of Radiology, Maastricht University Medical Centre, NUTRIM School for Nutrition and Translational Research in Metabolism, The Netherlands.
Wouter van Marken LichtenbeltDepartment of Nutrition and Movement Sciences, Maastricht Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, The Netherlands.
Patrick SchrauwenDepartment of Nutrition and Movement Sciences, Maastricht Medical Centre, NUTRIM School of Nutrition and Translational Research in Metabolism, The Netherlands. Electronic address: p.schrauwen@maastrichtuniversity.nl.
Maastricht University Medical Centre · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveResveratrol supplementation improves metabolic health in healthy obese men, but not in patients with type 2 diabetes (T2D) when given as add-on therapy. Therefore, we examined whether resveratrol can enhance metabolic health in men at risk of developing T2D. Additionally, we examined if resveratrol can stimulate brown adipose tissue (BAT).

methodsThirteen male first degree relatives (FDR) of patients with T2D received resveratrol (150 mg/day) and placebo for 30 days in a randomized, placebo controlled, cross-over trial.

resultsResveratrol significantly improved ex vivo muscle mitochondrial function on a fatty acid-derived substrate. However, resveratrol did not improve insulin sensitivity, expressed as the rate of glucose disposal during a two-step hyperinsulinemic-euglycemic clamp. Also, intrahepatic and intramyocellular lipid content, substrate utilization, energy metabolism, and cold-stimulated

conclusionsResveratrol stimulates muscle mitochondrial function in FDR males, which is in concordance with previous results. However, no other metabolic benefits of resveratrol were found in this group. This could be attributed to subject characteristics causing alterations in metabolism of resveratrol and thereby affecting resveratrol's effectiveness. CLINICALTRIALS. GOV ID: NCT02129595.

Indexed as

Insulin ResistanceAdipose Tissue, BrownAgedDiabetes Mellitus, Type 2Fatty AcidsGlucoseHumansHypoglycemic AgentsMaleMiddle AgedMitochondria, MusclePedigreeResveratrolFatty AcidsGlucoseHypoglycemic AgentsResveratrolBrown adipose tissueInsulin sensitivityMitochondrial functionPre-diabetesResveratrolType 2 diabetes

Identifiers

PMID29706321
PMCPMC6001939
OpenAlexW2801147755

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.